The FDA granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer who progressed on or are intolerant to crizotinib.
The FDA recommended a dose of 90 mg orally once daily for the first 7 days. After that, if tolerated, the dose can be increased to 180 mg orally once daily.
This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.
American Association for Cancer Research Annual Meeting
View past polls
Search Healio's robust listing of national and international medical meetings.
©2017 All Rights Reserved.